Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder

Imagem de Miniatura
Arquivos
art_COSTA_Dissecting_the_YaleBrown_ObsessiveCompulsive_Scale_severity_scale_to_2017.PDF (328.36 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SAGE PUBLICATIONS LTD
Autores
BARBOSA, Veronica S.
Citação
JOURNAL OF PSYCHOPHARMACOLOGY, v.31, n.10, p.1312-1322, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
We aimed to investigate which items of the Yale-Brown Obsessive-Compulsive Severity Scale best discriminate the reduction in total scores in obsessive-compulsive disorder patients after 4 and 12 weeks of pharmacological treatment. Data from 112 obsessive-compulsive disorder patients who received fluoxetine (<= 80 mg/day) for 12 weeks were included. Improvement indices were built for each Yale-Brown Obsessive-Compulsive Severity Scale item at two timeframes: from baseline to week 4 and from baseline to week 12. Indices for each item were correlated with the total scores for obsessions and compulsions and then ranked by correlation coefficient. A correlation coefficient. >= 0.7 was used to identify items that contributed significantly to reducing obsessive-compulsive disorder severity. At week 4, the distress items reached the threshold of 0.7 for improvement on the obsession and compulsion subscales although, contrary to our expectations, there was greater improvement in the control items than in the distress items. At week 12, there was greater improvement in the time, interference, and control items than in the distress items. The use of fluoxetine led first to reductions in distress and increases in control over symptoms before affecting the time spent on, and interference from, obsessions and compulsions. Resistance did not correlate with overall improvement. Understanding the pathway of improvement with pharmacological treatment in obsessive-compulsive disorder may provide clues about how to optimize the effects of medication.
Palavras-chave
Obsessive-compulsive disorder, serotonin reuptake inhibitor, clinical trial
URI
https://observatorio.fm.usp.br/handle/OPI/24484
Referências
  1. Alenina N, 2006, STEM CELL REV, V2, P5, DOI 10.1385/SCR:2:1:5
  2. American Psychiatric Association, 2000, DIAGN STAT MAN MENT
  3. Baldwin DS, 2005, J PSYCHOPHARMACOL, V19, P567, DOI 10.1177/0269881105059253
  4. Bandelow B, 2012, INT J PSYCHIAT CLIN, V16, P77, DOI 10.3109/13651501.2012.667114
  5. Belotto-Silva C, 2012, J ANXIETY DISORD, V26, P25, DOI 10.1016/j.janxdis.2011.08.008
  6. Bergqvist PBF, 1999, BIOL PSYCHIAT, V45, P164, DOI 10.1016/S0006-3223(98)00154-1
  7. Besiroglu L, 2011, COMPR PSYCHIAT, V52, P556, DOI 10.1016/j.comppsych.2010.10.003
  8. Blier P, 1998, BIOL PSYCHIAT, V44, P313, DOI 10.1016/S0006-3223(98)00114-0
  9. Bloch MH, 2006, MOL PSYCHIATR, V11, P622, DOI 10.1038/sj.mp.4001823
  10. Bonett DG, 2002, STAT MED, V21, P1331, DOI 10.1002/sim.1108
  11. Bonett DG, 2002, PSYCHOL METHODS, V7, P370, DOI 10.1037//1082-989X.7.3.370
  12. Cavanagh K, 2014, BEHAV COGN PSYCHOTH, V42, P497, DOI 10.1017/S1352465813000568
  13. Costa DLD, 2013, J PSYCHIATR RES, V47, P1700, DOI 10.1016/j.jpsychires.2013.07.006
  14. Deacon BJ, 2005, J ANXIETY DISORD, V19, P573, DOI 10.1016/j.janxdis.2004.04.009
  15. Diniz JB, 2011, J CLIN PSYCHOPHARM, V31, P763, DOI 10.1097/JCP.0b013e3182367aee
  16. Eisen JL, 2006, COMPR PSYCHIAT, V47, P272, DOI 10.1016/j.comppsych.2005.11.006
  17. ELMANSARI M, 1995, NEUROPSYCHOPHARMACOL, V13, P117, DOI 10.1016/0893-133X(95)00045-F
  18. EMMELKAMP PMG, 1991, BEHAV RES THER, V29, P293, DOI 10.1016/0005-7967(91)90120-R
  19. ERNST E, 1995, BRIT MED J, V311, P551
  20. Erzegovesi S, 2001, J CLIN PSYCHOPHARM, V21, P488, DOI 10.1097/00004714-200110000-00006
  21. FALSSTEWART W, 1992, PSYCHOL REP, V70, P239, DOI 10.2466/PR0.70.1.239-240
  22. Foa Edna B, 2010, Dialogues Clin Neurosci, V12, P199
  23. GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006
  24. GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1012
  25. Heinz A, 1999, PHARMACOPSYCHIATRY, V32, P223, DOI 10.1055/s-1999-7959
  26. Hesse S, 2005, PSYCHIAT RES-NEUROIM, V140, P63, DOI 10.1016/j.psychresns.2005.07.002
  27. Hollander E, 2010, J CLIN PSYCHIAT, V71, P784, DOI 10.4088/JCP.09m05911blu
  28. Jacoby RJ, 2014, COMPR PSYCHIAT, V55, P1195, DOI 10.1016/j.comppsych.2014.03.011
  29. KIM SW, 1994, PSYCHIAT RES, V51, P203, DOI 10.1016/0165-1781(94)90039-6
  30. Koran LM, 2007, AM J PSYCHIAT, V164, P5
  31. MCKAY D, 1995, BEHAV RES THER, V33, P865, DOI 10.1016/0005-7967(95)00014-O
  32. McKay D, 1998, J PSYCHOPATHOL BEHAV, V20, P265, DOI 10.1023/A:1023019419065
  33. McQueen D, 2013, ADV PSYCHIAT TREATME, V19, P162, DOI 10.1192/APT.BP.112.010397]
  34. Micallef J, 2001, CLIN NEUROPHARMACOL, V24, P191, DOI 10.1097/00002826-200107000-00002
  35. Moritz S, 2002, PSYCHIAT RES, V109, P193, DOI 10.1016/S0165-1781(02)00012-4
  36. Ramos-Cerqueira Ana Teresa de Abreu, 2008, Depress Anxiety, V25, P1020, DOI 10.1002/da.20431
  37. Rosa AC, 2012, J PSYCHIATR RES, V46, P1286, DOI 10.1016/j.jpsychires.2012.05.019
  38. Saxena S, 2000, PSYCHIAT CLIN N AM, V23, P563, DOI 10.1016/S0193-953X(05)70181-7
  39. Shavitt RG, 2014, J PSYCHIATR RES, V57, P141, DOI 10.1016/j.jpsychires.2014.06.010
  40. Simpson HB, 2013, JAMA PSYCHIAT, V70, P1190, DOI 10.1001/jamapsychiatry.2013.1932
  41. Storch EA, 2010, PSYCHOL ASSESSMENT, V22, P223, DOI 10.1037/a0018492
  42. Storch EA, 2010, J ANXIETY DISORD, V24, P650, DOI 10.1016/j.janxdis.2010.04.010
  43. VANOPPEN P, 1994, BEHAV RES THER, V32, P79, DOI 10.1016/0005-7967(94)90086-8
  44. VANOPPEN P, 1995, BEHAV RES THER, V33, P379, DOI 10.1016/0005-7967(94)00052-L

Coleções
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/21